NCT01528787 - Study of AR-13324 in Patients With Elevated Intraocular Pressure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Ocular HypertensionOpen Angle Glaucoma

Interventions

DRUG

AR-13324 Ophthalmic Solution 0.01%

Administered to study eye, once daily (QD) in the morning (AM) for 7 days

DRUG

AR-13324 Ophthalmic Solution 0.02%

Administered to study eye, QD AM for 7 days

DRUG

AR-13324 Ophthalmic Solution 0.04%

Administered to study eye, QD AM for 7 days

OTHER

AR-13324 Ophthalmic Solution Vehicle

Administered to study eye, QD AM for 7 days

Trial Locations (11)

Rochester Ophthalmology Group, Rochester

Wills Eye Hospital, Philadelphia

Coastal Research Associates, LLC, Roswell

Univ Eye Surgeons, Maryville Ctr., Maryville

Comprehensive Eye Care, St Louis

Heart of America Eye Care, P.A., Shawnee Mission

The Eye Institute, Tulsa

Medical Center Ophthalmology Associates, San Antonio

Texan Eye, Austin

Aesthetic Eye Care Institute, Newport Beach

Robert Noecker, M.D., M.B.A., Fairfield